Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas
Abstract Background This study aimed to investigate the safety and efficacy of fourth-generation combined PSMA and GD2-targeted chimeric antigen receptor (CAR)-T cells in the treatment of refractory/relapsed gliomas. Method This study employed a single-arm design, enrolling patients with confirmed r...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-025-06523-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850111657627353088 |
|---|---|
| author | Jinshan Gu Jiasheng Li Yang Xu Ge Zhang Jingyi Xie Rui Jia Wei Chen Zhengfeng Lu Chengwei Chang Haijun Wen Lung-ji Chang Huajuan Ma Qichun Cai |
| author_facet | Jinshan Gu Jiasheng Li Yang Xu Ge Zhang Jingyi Xie Rui Jia Wei Chen Zhengfeng Lu Chengwei Chang Haijun Wen Lung-ji Chang Huajuan Ma Qichun Cai |
| author_sort | Jinshan Gu |
| collection | DOAJ |
| description | Abstract Background This study aimed to investigate the safety and efficacy of fourth-generation combined PSMA and GD2-targeted chimeric antigen receptor (CAR)-T cells in the treatment of refractory/relapsed gliomas. Method This study employed a single-arm design, enrolling patients with confirmed refractory/relapsed gliomas at the Immuno-oncology Department of the Cancer Center at Clifford Hospital in Guangdong. Eligible patients received combined treatment with PSMA CAR-T and GD2 CAR-T cells via intravenous administration. The dose of reinfused CAR-T cells ranged from 1–5 × 10^6 cells/kg of body weight. Results Six patients were included in the study, all of whom responded to the treatment. The overall response rate (ORR) was 50%, with three patients achieving complete response (CR) (50%) and three demonstrating stable disease (SD) (50%). The median progression-free survival (PFS) was 9.0 months (range, 1–56 months), and the median overall survival (OS) was 24.5 months (range, 13–63 months). Three patients (50%) developed cytokine release syndrome (CRS), all of which were classified as grade I CRS, and no patients experienced immune effector cell-associated neurotoxicity Syndrome (ICANS). Conclusion Combined PSMA CAR-T and GD2 CAR-T cell therapy demonstrated significant efficacy and good tolerability in the treatment of refractory/relapsed gliomas, without severe adverse reactions. |
| format | Article |
| id | doaj-art-03200e5bd4a04827bfacb689b883662f |
| institution | OA Journals |
| issn | 1479-5876 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj-art-03200e5bd4a04827bfacb689b883662f2025-08-20T02:37:35ZengBMCJournal of Translational Medicine1479-58762025-05-0123111310.1186/s12967-025-06523-1Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomasJinshan Gu0Jiasheng Li1Yang Xu2Ge Zhang3Jingyi Xie4Rui Jia5Wei Chen6Zhengfeng Lu7Chengwei Chang8Haijun Wen9Lung-ji Chang10Huajuan Ma11Qichun Cai12Immuno-oncology department of the cancer center, 21 st Floor, Building 2, Guangdong Clifford HospitalState Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-Sen UniversityState Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-Sen UniversityImmuno-oncology department of the cancer center, 21 st Floor, Building 2, Guangdong Clifford HospitalImmuno-oncology department of the cancer center, 21 st Floor, Building 2, Guangdong Clifford HospitalImmuno-oncology department of the cancer center, 21 st Floor, Building 2, Guangdong Clifford HospitalImmuno-oncology department of the cancer center, 21 st Floor, Building 2, Guangdong Clifford HospitalImmuno-oncology department of the cancer center, 21 st Floor, Building 2, Guangdong Clifford HospitalShenzhen Geno-Immune Medical InstituteState Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-Sen UniversityShenzhen Geno-Immune Medical InstituteImmuno-oncology department of the cancer center, 21 st Floor, Building 2, Guangdong Clifford HospitalImmuno-oncology department of the cancer center, 21 st Floor, Building 2, Guangdong Clifford HospitalAbstract Background This study aimed to investigate the safety and efficacy of fourth-generation combined PSMA and GD2-targeted chimeric antigen receptor (CAR)-T cells in the treatment of refractory/relapsed gliomas. Method This study employed a single-arm design, enrolling patients with confirmed refractory/relapsed gliomas at the Immuno-oncology Department of the Cancer Center at Clifford Hospital in Guangdong. Eligible patients received combined treatment with PSMA CAR-T and GD2 CAR-T cells via intravenous administration. The dose of reinfused CAR-T cells ranged from 1–5 × 10^6 cells/kg of body weight. Results Six patients were included in the study, all of whom responded to the treatment. The overall response rate (ORR) was 50%, with three patients achieving complete response (CR) (50%) and three demonstrating stable disease (SD) (50%). The median progression-free survival (PFS) was 9.0 months (range, 1–56 months), and the median overall survival (OS) was 24.5 months (range, 13–63 months). Three patients (50%) developed cytokine release syndrome (CRS), all of which were classified as grade I CRS, and no patients experienced immune effector cell-associated neurotoxicity Syndrome (ICANS). Conclusion Combined PSMA CAR-T and GD2 CAR-T cell therapy demonstrated significant efficacy and good tolerability in the treatment of refractory/relapsed gliomas, without severe adverse reactions.https://doi.org/10.1186/s12967-025-06523-1Refractory/relapsed gliomasPSMA CAR-T therapyGD2 CAR-T therapyCombination therapy |
| spellingShingle | Jinshan Gu Jiasheng Li Yang Xu Ge Zhang Jingyi Xie Rui Jia Wei Chen Zhengfeng Lu Chengwei Chang Haijun Wen Lung-ji Chang Huajuan Ma Qichun Cai Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas Journal of Translational Medicine Refractory/relapsed gliomas PSMA CAR-T therapy GD2 CAR-T therapy Combination therapy |
| title | Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas |
| title_full | Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas |
| title_fullStr | Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas |
| title_full_unstemmed | Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas |
| title_short | Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas |
| title_sort | preliminary exploration of psma car t combined with gd2 car t for the treatment of refractory relapsed gliomas |
| topic | Refractory/relapsed gliomas PSMA CAR-T therapy GD2 CAR-T therapy Combination therapy |
| url | https://doi.org/10.1186/s12967-025-06523-1 |
| work_keys_str_mv | AT jinshangu preliminaryexplorationofpsmacartcombinedwithgd2cartforthetreatmentofrefractoryrelapsedgliomas AT jiashengli preliminaryexplorationofpsmacartcombinedwithgd2cartforthetreatmentofrefractoryrelapsedgliomas AT yangxu preliminaryexplorationofpsmacartcombinedwithgd2cartforthetreatmentofrefractoryrelapsedgliomas AT gezhang preliminaryexplorationofpsmacartcombinedwithgd2cartforthetreatmentofrefractoryrelapsedgliomas AT jingyixie preliminaryexplorationofpsmacartcombinedwithgd2cartforthetreatmentofrefractoryrelapsedgliomas AT ruijia preliminaryexplorationofpsmacartcombinedwithgd2cartforthetreatmentofrefractoryrelapsedgliomas AT weichen preliminaryexplorationofpsmacartcombinedwithgd2cartforthetreatmentofrefractoryrelapsedgliomas AT zhengfenglu preliminaryexplorationofpsmacartcombinedwithgd2cartforthetreatmentofrefractoryrelapsedgliomas AT chengweichang preliminaryexplorationofpsmacartcombinedwithgd2cartforthetreatmentofrefractoryrelapsedgliomas AT haijunwen preliminaryexplorationofpsmacartcombinedwithgd2cartforthetreatmentofrefractoryrelapsedgliomas AT lungjichang preliminaryexplorationofpsmacartcombinedwithgd2cartforthetreatmentofrefractoryrelapsedgliomas AT huajuanma preliminaryexplorationofpsmacartcombinedwithgd2cartforthetreatmentofrefractoryrelapsedgliomas AT qichuncai preliminaryexplorationofpsmacartcombinedwithgd2cartforthetreatmentofrefractoryrelapsedgliomas |